FDA WARNING_LETTER - Fancy Meds, LLC dba Fancy Meds - August 31, 2025

The FDA issued a warning letter to Fancy Meds on September 9, 2025, following a review of their website in August 2025. The inspection revealed that Fancy Meds was offering compounded drug products, including semaglutide and tirzepatide, with misleading claims. These claims suggested that the compounded products were equivalent to FDA-approved drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound, which is not accurate since compounded drugs are not FDA-approved.

The main violations identified fall under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA), which prohibit false or misleading labeling and advertising. Consequently, the products are considered misbranded, and their introduction into interstate commerce violates section 301(a) of the FDCA.

The FDA requires Fancy Meds to take immediate corrective actions, including ceasing the use of misleading language on their website. The company must provide a written response within 15 working days detailing the steps taken to rectify the violations and prevent future occurrences. Failure to comply may result in legal actions such as product seizure or injunctions. Fancy Meds is also advised to submit documentation supporting their compliance efforts to the Office of Compounding Quality and Compliance. If the company believes their products are not in violation, they must provide supporting information for FDA review.